

# LOGIX BUILDTECH PRIVATE LIMITED

Reg. Office:-DGL006, Ground Floor, DLF Galleria, Mayapour Vihar Phase-1, New Delhi-110091  
Corporate Identification Number:-U70200DL2010PTC20042, E-mail:corporate@logixgroup.in

## ANNEXURE I

(Regulation 52(8), read with Regulation 52(4), of the SEBI (LODR) Regulations, 2015

## STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2024

(All amounts in INR lakhs, unless otherwise stated)

S. No.	PARTICULARS	Quarter Ended			Year Ended	
		31.03.2024	31.12.2023	31.03.2023	31.03.2024	31.03.2023
		Audited	Unaudited	Audited	Audited	Audited
1.	Total Income from Operations	2,479.32	2,549.56	2,647.32	9,855.20	10,417.47
2.	Profit / (Loss) before tax, exceptional items	(3,052.16)	(3,104.08)	(2,978.24)	(12,795.37)	(13,883.90)
3.	Profit / (Loss) before tax & after exceptional items	(3,052.16)	(3,104.08)	(2,978.24)	(12,795.37)	(13,883.90)
4.	Profit / (Loss) after tax, exceptional items	(2,276.37)	(2,311.61)	(2,219.47)	(9,515.68)	(10,446.85)
5.	Total comprehensive income/(loss) for the year (net of tax)	(2,267.37)	(2,311.41)	(2,222.34)	(9,506.09)	(10,446.07)
6.	Paid up Equity Share Capital	2,054.75	2,054.75	2,054.75	2,054.75	2,054.75
7.	Reserves (excluding Revaluation Reserve)	(3,431.42)	(1,164.05)	6,074.67	(3,431.42)	6,074.67
8.	Net Worth	(1,376.67)	890.70	8,129.42	(1,376.67)	8,129.42
9.	Paid up Debt Capital/Outstanding Debt	1,16,190.00	1,17,450.00	1,17,720.00	1,16,190.00	1,17,720.00
10.	Outstanding Redeemable Preference Shares	—	—	—	—	—
11.	Debt Equity Ratio	(84.40)	131.86	14.48	(84.40)	14.48
12.	Earnings per equity share					
	(i) Basic (in INR)	(11.08)	(11.25)	(10.80)	(46.31)	(50.84)
	(ii) Diluted (in INR)	(11.08)	(11.25)	(10.80)	(46.31)	(50.84)
13.	Capital Redemption Reserve	—	—	—	—	—
14.	Debenture Redemption Reserve	—	—	—	—	—
15.	Debt Service Coverage Ratio	0.26	0.27	0.21	0.26	0.21
16.	Interest Service Coverage Ratio	0.31	0.31	0.32	0.28	0.23

### Notes:

- a) The above is an extract of the detailed format of annual financial results filed with the Stock exchange under Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the annual financial results are available on the website of the Stock Exchange (www.bseindia.com) and the listed entity (www.logixgroup.in).
- b) For the items referred in Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the pertinent disclosures have been made to the Stock exchange (BSE India) and can be accessed on the URL (www.bseindia.com) and website (www.logixgroup.in).
- c) The company was unable to redeem the debentures on the redemption date 04-11-2023, due to adverse market conditions in the real estate industry. Talks are in progress with the debenture trustee and debenture holders / lenders in order to mutually agree on an extension of the redemption date and also in talks with the lenders and potential third-party buyers to purchase the secured assets of the company to fund the redemption of the debentures.

For and on behalf of the Board of Directors

Place: Noida

Date: May 30, 2024

Sd/-  
Davender Mohan Saxena  
Director  
DIN: 01304559

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY OUTSIDE INDIA.

Initial public offer of Equity Shares (as defined below) on the main board of the Stock Exchanges (defined below) in compliance with Chapter II of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended.

## PUBLIC ANNOUNCEMENT



## AKUMS DRUGS AND PHARMACEUTICALS LIMITED



(Please scan this QR code to view the DRHP)

Our Company was incorporated as a public company, limited by shares, under the Companies Act, 1956, as amended, in the name of 'Akums Drugs and Pharmaceuticals Limited', pursuant to a certificate of incorporation dated April 19, 2004 issued by the Registrar of Companies, Delhi and Haryana in New Delhi ("RoC"). Our Company received a certificate of commencement of business issued by the RoC dated May 13, 2004.

Registered Office: 304, Mohan Place, LSC Saraswati Vihar, Delhi – 110 034, India

Corporate Office: Plot no. 131 to 133, Block C, Mangolpuri, Ind. Area, Phase 1, Delhi – 110 083, India

Telephone: + 91 11 6904 1000; Contact person: Dharamvir Malik, Company Secretary and Compliance Officer

E-mail: cs@akums.net; Website: www.akums.in; Corporate Identity Number: U24239DL2004PLC125888

## NOTICE TO INVESTORS ("NOTICE")

INITIAL PUBLIC OFFER OF UP TO [•] EQUITY SHARES OF FACE VALUE OF ₹ 2 EACH ("EQUITY SHARES") OF AKUMS DRUGS AND PHARMACEUTICALS LIMITED ("COMPANY" OR "ISSUER") FOR CASH AT A PRICE OF ₹ [•] PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹ [•] PER EQUITY SHARE) ("OFFER PRICE") AGGREGATING UP TO ₹ [•] MILLION COMPRISING A FRESH ISSUE OF UP TO [•] EQUITY SHARES AGGREGATING UP TO ₹ 6.800 MILLION BY OUR COMPANY ("FRESH ISSUE") AND AN OFFER FOR SALE OF UP TO 18,598,365 EQUITY SHARES AGGREGATING UP TO ₹ [•] MILLION ("OFFERED SHARES") BY THE SELLING SHAREHOLDERS, COMPRISING UP TO 2,145,965 EQUITY SHARES AGGREGATING UP TO ₹ [•] MILLION BY SANJEEV JAIN, UP TO 2,145,965 EQUITY SHARES AGGREGATING UP TO ₹ [•] MILLION BY SANDEEP JAIN (TOGETHER THE "PROMOTER SELLING SHAREHOLDERS") AND UP TO 14,306,435 EQUITY SHARES AGGREGATING UP TO ₹ [•] MILLION BY RUBY QC INVESTMENT HOLDINGS PTE. LTD. (THE "INVESTOR SELLING SHAREHOLDER") (THE PROMOTER SELLING SHAREHOLDERS AND THE INVESTOR SELLING SHAREHOLDER, COLLECTIVELY REFERRED TO AS THE "SELLING SHAREHOLDERS") ("OFFER FOR SALE", TOGETHER WITH THE FRESH ISSUE, THE "OFFER").

Potential Bidders may note the following as a corrigendum cum addendum ("Addendum") to the draft red herring prospectus dated February 10, 2024, filed our Company with the Securities and Exchange Board of India and Stock Exchanges ("DRHP"):

On May 29, 2024, Ruby QC Holdings Pte. Ltd., the Investor Selling Shareholder ("Ruby QC"), has waived one of its exit right (the "Buy-back Waiver") under Clause 8.10(ii)(b) of the shareholders' agreement dated October 3, 2019 ("SHA"), entered into by and amongst our Company, its individual Promoters, namely, Sandeep Jain, Sanjeev Jain, and Ruby QC read with the Waiver cum Amendment Agreement dated February 9, 2024 and undertaking dated May 15, 2024 to the SHA and such right shall be of no further force or effect without any further act or deed required by any party to the SHA. This Buy-back Waiver effected in relation to the provisions of the SHA shall also be deemed to be a waiver under the corresponding provisions of the Articles of Association of our Company.

Accordingly, pursuant to the Buy-back Waiver, Ruby QC's exit right under Clause 8.10(ii)(b) of the SHA has been waived in its entirety with effect from May 29, 2024. Accordingly, the Company is no longer required to buy-back the Equity Shares held by Ruby QC in the event the Company and/or its Promoters are unable to facilitate an exit for Ruby QC.

Please note that since the buy-back option under Clause 8.10(ii)(b) of the SHA was part of a waterfall mechanism and could only be triggered if the Offer was not consummated by December 31, 2024 and a secondary sale was not facilitated by the Company and its Promoters of the Equity Shares held by Ruby QC, irrespective of the Buy-back Waiver, the Company's obligation to buy-back the Equity Shares held by Ruby QC was not in operation as on the date of filing of the DRHP, i.e., February 10, 2024.

Based on above, we confirm that the Company, any of its Directors and the Book Running Lead Managers have not entered into any buy-back arrangements for purchase of Equity Shares from any person.

Please note that this Addendum does not reflect all the changes that have occurred between the date of filing of the DRHP with the SEBI and the Stock Exchanges and the date hereof, and accordingly, does not include all the changes and/ or updates that will be included in the RHP and the Prospectus. The information in this Addendum supplements and updates the information in the DRHP and the above changes are to be read in conjunction with the DRHP and accordingly, relevant references in the DRHP stand updated pursuant to this Addendum. Potential Bidders should read this Addendum in conjunction with the DRHP.

This Addendum which has been filed with SEBI and the Stock Exchanges shall be made available to the public for comments, if any, for a period of at least 21 days, from the date of such filing with SEBI and the Stock Exchanges and will be available on their website www.sebi.gov.in, the websites of the Stock Exchanges i.e., www.nseindia.com, www.bseindia.com, the website of the Company i.e. www.akums.in and the website of the BRLMs, i.e., ICICI Securities Limited at www.icicisecurities.com, Axis Capital Limited at www.axiscapital.co.in, Citigroup Global Markets India Private Limited at www.online.citibank.co.in and Ambit Private Limited at www.ambit.co.

Capitalized terms used in this Addendum shall, unless the context otherwise requires, have the meaning ascribed to them in the DRHP.

BOOK RUNNING LEAD MANAGERS			
<b>ICICI Securities Limited</b> ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai 400 025 Maharashtra, India Tel: +91 22 6807 7100 E-mail: akums ipo@icicisecurities.com Investor grievance e-mail: customercare@icicisecurities.com Website: www.icicisecurities.com Contact Person: Namrata Ravasia / Harsh Thakkar SEBI Registration No.: INM000011179	<b>Axis Capital Limited</b> 1 <sup>st</sup> Floor, Axis House, C-2 Wadia International Centre, Pandurang Budhkar Marg, Worli, Mumbai 400 025, Maharashtra, India Tel: +91 22 4325 2183 E-mail: akums.ipo@axiscap.in Investor grievance e-mail: complaints@axiscap.in Website: www.axiscapital.co.in Contact Person: Akash Aggarwal / Jigar Jain SEBI Registration No.: INM000012029	<b>Citigroup Global Markets India Private Limited</b> 1202, 12 <sup>th</sup> Floor, First International Financial Centre, G-Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 098, Maharashtra, India Tel: +91 22 6175 9999 E-mail: akums.ipo@citi.com Investor Grievance ID: investors.cgmb@citi.com Website: www.online.citibank.co.in/rhtm/citigroupglobalscreen1.htm Contact Person: Abhishek Mawandiya SEBI Registration Number: INM000010718	<b>Ambit Private Limited</b> Ambit House, 449, Senapati Bapat Marg, Lower Parel, Mumbai 400 013 Maharashtra, India Tel: + 91 22 6623 3030 E-mail: akums.ipo@ambit.co Investor Grievance E-mail: customerservice@ambit.co Website: www.ambit.co Contact person: Siddhesh Deshmukh SEBI registration number: INM000010585
REGISTRAR TO THE OFFER			
	<b>Link Intime India Private Limited</b> C-101, 1 <sup>st</sup> Floor, 247 Park, Lal Bahadur Shastri Marg, Vikhroli (West), Mumbai 400 083, Maharashtra, India Tel: +91 810 811 4949; E-mail: akumsdrugs.ipo@linkintime.co.in; Website: www.linkintime.co.in Investor Grievance ID: akumsdrugs.ipo@linkintime.co.in; Contact Person: Shanti Gopalkrishnan SEBI Registration Number: INR000004058		

For AKUMS DRUGS AND PHARMACEUTICALS LIMITED

On behalf of the Board of Directors

Place: New Delhi

Date: May 31, 2024

Sd/-  
Dharamvir Malik  
Company Secretary & Compliance Officer

AKUMS DRUGS AND PHARMACEUTICALS LIMITED is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares and has filed the DRHP dated February 10, 2024, with SEBI on February 11, 2024. The DRHP shall be available on the website of SEBI at www.sebi.gov.in, the websites of the Stock Exchanges i.e., BSE and NSE at www.bseindia.com and www.nseindia.com, respectively, and the websites of the BRLMs, i.e., ICICI Securities Limited, Axis Capital Limited, Citigroup Global Markets India Private Limited and Ambit Private Limited at www.icicisecurities.com, www.axiscapital.co.in, www.online.citibank.co.in/rhtm/citigroupglobalscreen1.htm and www.ambit.co, respectively. Potential Bidders should note that investment in equity shares involves a high degree of risk and for details relating to such risk, please see the section titled "Risk Factors" of the RHP, once filed. Potential Bidders should not rely on the DRHP filed with SEBI for making any investment decision and must rely on their own examination of our Company and the Offer, including the risks involved.

This announcement does not constitute an invitation or offer of securities for sale in any jurisdiction. The Equity Shares offered in the Offer have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended ("U.S. Securities Act") and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, the Equity Shares are being offered and sold (a) within the United States solely to "qualified institutional buyers" (as defined in Rule 144A under the U.S. Securities Act) pursuant to Section 4(a) of the U.S. Securities Act, and (b) outside the United States in offshore transactions as defined in and in compliance with Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales are made. There will be no public offering of securities in the United States.

Adfactors

## FINANCIAL EXPRESS

## D S KULKARNI DEVELOPERS LIMITED

CIN No: L45201PN1991PLC063340

Regd Office: Unit # 301, 3rd Floor, Swojas One, Kolhrud, Pune - 411038

Phone: 020-67166716 Email: cs.dskdl@ashdanproperties.in, Website: www.dskcnp.com

Extract of Financial Results for the Quarter ended and year ended 31st March, 2024

(Rs. In Lakhs)

Sr. No.	Particulars	Quarter Ended			Year Ended	Year Ended
		31-03-2024	31-12-23	31-03-2023	31-03-24	31-03-23
		Audited	Unaudited	Audited	Audited	Audited
1.	Total Income from Operations	2,823.91	-	-	2,823.91	-
2.	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	(3.81)	(213.88)	(94,119.83)	(888.32)	(63,564.66)
3.	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	(3.81)	(213.88)	(94,119.83)	(888.32)	(40,506.10)
4.	Total Comprehensive Income for the period [Comprising Profit/ (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(3.81)	(213.88)	(94,119.83)	(888.32)	(40,506.10)
5.	Total Comprehensive Income for the period [Comprising Profit/ (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(3.81)	(213.88)	(94,119.83)	(888.32)	(40,506.10)
6.	Paid-up Equity Share Capital	1,000.00	1,000.00	2,580.10	1,000.00	2,580.10
7.	Other Equity	(15,514.28)	(15,151.74)	(16,836.25)	(15,154.36)	(16,836.14)
8.	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations) -					
(a) Basic		(0.04)	(2.14)	(364.79)	(8.88)	(156.99)
(b) Diluted		(0.04)	(2.14)	(364.79)	(8.88)	(156.99)

Notes : The Board of Directors has approved the above audited Standalone financial results for the quarter and year ended 31st March, 2024 and its release at their meeting held on 30th May, 2024. The full format of the financial results are available on the websites of the Stock Exchanges i.e. www.bseindia.com, www.nseindia.com and on the website of the Company at www.dskcnp.com.

For D S Kulkarni Developers Limited

Sd/-

Bhushan Vilaskumar Palresha

Managing Director

DIN: 01258918

Date : 30.05.2024

Place : Pune

(This is an Advertisement for information purposes only and not for publication or distribution outside India and is not an Offer Document announcement)



# SOBHAGYA MERCANTILE LIMITED

(CIN: L45100MH1983PLC031671)

Our Company was incorporated as 'Sobhagya Mercantile Limited' on December 27, 1983 as a public limited company under the Companies Act, 1956 with the Registrar of Companies, Maharashtra at Mumbai.

The current promoters of the Company, pursuant to a Share Purchase Agreement entered into with the erstwhile promoters/ members of the promoter group for the acquisition of 82,830 Equity Shares representing 34.51% of the share capital of the Company, acquired control of the Company after making an open offer to the public shareholders under the SEBI (SAST) Regulations, in the year 2019.

Our Company further altered its Object Clause to enable the Company to carry on the activities of infrastructure and real estate business, on account of the experience of the new management in large scale infrastructure sector. The Equity Shares of our Company are listed on the BSE.

Registered Office: B-61, Floor 6, Plot No: 210, B-Wing Mittal Tower, Free Press Journal Marg, Nariman Point, Mumbai 400 021, Maharashtra. Tel: +91 22 22882125

Corporate Office: 526, 1st Floor Bhangdiya House, Near Getwell Hospital, Dhanoli, Nagpur 440 012, Maharashtra Tel: +91 712 2460120

Contact person: Mrs. Shalinee Singh, Company Secretary and Compliance Officer. E-mail id: shalinee.s@themksgroup.com; | Website: www.sobhagyaltd.com

## PROMOTERS OF OUR COMPANY: SHRIKANT BHANGDIYA; MANISHA OMPRAKASH MANIYAR; MEGHA MITESH BHANGDIYA; AARTI SHRIKANT BHANGDIYA AND SONAL KIRTIKUMAR BHANGDIYA

ISSUE OF UP TO 81,60,000 FULLY PAID-UP EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH OF OUR COMPANY (THE "RIGHTS EQUITY SHARES") FOR CASH AT A PRICE OF ₹ 21/- PER RIGHTS EQUITY SHARE AGGREGATING TO ₹ 1713.60 LAKHS ON A RIGHTS BASIS TO THE ELIGIBLE EQUITY SHAREHOLDERS OF OUR COMPANY IN THE RATIO OF 34 (THIRTY FOUR) RIGHTS EQUITY SHARES FOR EVERY 1 (ONE) FULLY PAID-UP EQUITY SHARE HELD BY THE ELIGIBLE EQUITY SHAREHOLDERS ON THE RECORD DATE, THAT IS ON TUESDAY, APRIL 23, 2024 ("RECORD DATE") (THE "ISSUE"). FOR FURTHER DETAILS, SEE "TERMS OF THE ISSUE" ON PAGE 171 OF THE LETTER OF OFFER.

## BASIS OF ALLOTMENT

The Board of Directors of Sobhagya Mercantile Limited wishes to thank all its shareholders and investors for the response to the Issue which opened for subscription on Monday, May 06, 2024 and closed on Tuesday, May 21, 2024 with the last date for on market renunciation of Rights Entitlements being Thursday, May 16, 2024. Out of the total 337 Applications for 10631524 Rights Equity Shares, 270 Applications for 187748 Rights Equity Shares were rejected (including nil Rights Equity Shares partially rejected) due to technical reasons as disclosed in the Letter of Offer. The total number of valid Applications received were 67 for 10443776 Rights Equity Shares, which was 127.99 % of the Rights Equity Shares Allotted under the Issue. The Basis of Allotment was finalized on Monday, May 27, 2024 by the Company in consultation with the Lead Manager to the Issue, the Registrar to the Issue and BSE, the Designated Stock Exchange for the Issue. The Board of Directors of the Company, at its meeting held on May 27, 2024, took on record the Basis of Allotment so approved, and approved the allotment of 81,60,000 Rights Equity Shares to the successful Applicants. In the Issue, no Rights Equity Shares have been kept in abeyance. We hereby confirm that all the valid Applications have been considered for Allotment.

1. The break-up of valid Applications received through ASBA (after technical rejections) is as under:

Category	Applications Received		Equity Shares Applied for				Equity Shares allotted	
	Number	%	Number	Value (₹)	%		Number	Value (₹)
Eligible Shareholders	62	92.54	9892676	207746196.00	94.72		8136730	170871330.00
Renouncees	5	7.46	551100	11573100.00	5.28		23270	488670.00
Total	67	100.00	10443776	219319296.00	100.00		8160000	171360000.00

2. Summary of Allotment is as under:

Category	No. of valid CAFs (including ASBA applications) received	No. of Rights Equity Shares accepted and Allotted against Rights Entitlement (A)	No. of Rights Equity Shares accepted and Allotted against Additional Rights Equity Shares applied for (B)	Total Rights Equity Shares accepted and allotted (A + B)
	Number	Number	Number	Number
Eligible Shareholders	62	4282840	3853890	8136730
Renouncees	5	23270	0	23270
Total	67	4306110	3853890	8160000

**Intimations for Allotment/refund/rejection cases:** The dispatch of allotment advice cum refund intimation and intimation for rejection, as applicable, to the Investors who have provided their email address, have been sent on their email address on May 31, 2024 and investors who have not provided their email address, is being physically dispatched to their address provided by the depositories, is being completed on May 31, 2024. The instructions to SCSBs for unblocking funds in case of ASBA Applications were given on May 28, 2024. The Listing application was filed with BSE on Tuesday, May 28, 2024 and subsequently the listing approvals were received on Thursday, May 30, 2024.

The credit of Rights Equity Shares in dematerialized form to respective demat accounts of Allottees was completed on Friday, May 31, 2024, by NSDL and CDSL respectively. For further details, see "Terms of the Issue - Allotment Advice or Refund/ Unblocking of ASBA Accounts" on page 195 of the Letter of Offer. The trading in the Rights Equity Shares issued in the Rights Issue shall commence on BSE upon receipt of trading permission, applications for the same are being made, and shall be traded under same ISIN INE754DD01018 as the existing Equity Shares of the Company. The trading is expected to commence on or about Monday, June 03, 2024. Further, in accordance with SEBI circular bearing reference - SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated January 22, 2020, the request for extinguishment of Rights Entitlements has been sent to NSDL & CDSL and has been extinguished on.

**INVESTORS MAY PLEASE NOTE THAT THE EQUITYSHARES CAN BE TRADED ON THE STOCK EXCHANGES ONLY IN DEMATERIALIZED FORM**

### DISCLAIMER CLAUSE OF SEBI

The Letter of Offer has not been filed with SEBI in terms of SEBI ICDR Regulations as the size of the issue is less than ₹5000 lakhs. The Investors are advised to refer to the full text, see "Other Regulatory and Statutory Disclosures- Disclaimer Clause of SEBI" on page 165 of the Letter of Offer.

**DISCLAIMER CLAUSE OF BSE (DESIGNATED STOCK EXCHANGE** "BSE Limited" ("the Exchange") has given vide its letter dated December 26, 2023, permission to this Company to use the Exchange's name in this Letter of Offer as the stock exchange on which this Company's securities are proposed to be listed. The Exchange has scrutinized this letter of offer for its limited internal purpose of deciding on the matter of granting the aforesaid permission to this Company. The Exchange does not in any manner:

- warrant, certify or endorse the correctness or completeness of any of the contents of this letter of offer; or
- warrant that this Company's securities will be listed or will continue to be listed on the Exchange; or
- take any responsibility for the financial or other soundness of this Company, its promoters, its management or any scheme or project of this Company;

and it should not for any reason be deemed or construed that this letter of offer has been cleared or approved by the Exchange. Every person who desires to apply for or otherwise acquires any securities of this Company may do so pursuant to independent inquiry, investigation and analysis and shall not have any claim against the Exchange whatsoever by reason of any loss which may be suffered by